TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04044300

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single screw fixation
Description: A single trans-iliac, trans-sacral screw will be inserted at the sacral one or sacral two level based upon fracture location.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single screw fixation
Description: A single trans-iliac, trans-sacral screw will be inserted at the sacral one or sacral two level based upon fracture location.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative
Description: Continued pain management and physical therapy.
Study: NCT02173860

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FFR-guided surgical revascularization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angio-guided surgical revascularization
Study: NCT01427985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine, Fentanyl, Mivacurium
Description: 1. Atropin 10µg/kg~2. Mivacurium 200µg/kg immediately followed by~3. Fentanyl 2µg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine, Fentanyl, Mivacurium
Description: 1. Atropin 10µg/kg~2. Fentanyl 2µg/kg, repeat max. two times~3. Mivacurium 200µg/kg
Study: NCT00625469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: 62.5mg orally bid for first month, followed by 125mg bid thereafter
Study: NCT02718755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Induction Phase:~30 mg/m2 by vein over 15-30 minutes on Days 1 - 5 of a 28 day cycle.~Consolidation Phase:~30 mg/m2 by vein over 15-30 minutes on Days 1 - 4 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction Phase:~2 grams/m2 by vein over approximately 2 hours on Days 1 - 5 of a 28 day cycle.~Consolidation Phase:~2 grams/m2 by vein over approximately 2 hours on Days 1 - 4 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: Induction Phase:~25,000 Units/m2 by vein (or intramuscularly) over 90-120 minutes on Days 1 - 7 of a 28 day cycle.~Consolidation Phase:~25,000 Units/m2 by vein (or intramuscularly) over 90-120 minutes every other day on Days 1, 3, 5, 7, 9, 11, 13, 15 of a 28 day cycle.
Study: NCT01628471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine in combination with genistein
Description: decitabine IV infusion ( 10 hrs total), doses from 60 to 500 mg/m2 + fixed daily oral dose of 300 mg genisteine
Study: NCT03015571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophagus inspection in Narrow Band imaging.
Description: During the endoscope withdrawal after cardia examination NBI will be used for esophagus inspection.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard High definition endoscopy.
Description: Whole procedure will be performed in standard High definition endoscopy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophagus inspection in Narrow Band imaging and increased care.
Description: During the endoscope withdrawal after cardia examination NBI will be used for esophagus inspection and with increased care of cervical inlet patches detection.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard High definition endoscopy and increased care.
Description: Whole procedure will be performed in standard High definition endoscopy with increased care of cervical inlet patches detection.
Study: NCT01166737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Debulking Surgery (surgery in recurrent ovarian disease)
Description: Surgery for Patients with platinum-sensitive recurrent ovarian cancer with a positive AGO-score predictive for complete tumor resection
Study: NCT00864643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and atorvastatin
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and atorvastatin 10 mg or 20 mg, tablets, orally, once daily for up to 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and atorvastatin 10 mg or 20 mg, tablets, orally, once daily for up to 6 weeks.
Study: NCT04046432

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vigiis 101-LAB
Description: examined the effects of the Vigiis 101-LAB capsules I or II (5 or 10 billion CFU/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin was used as a placebo.
Study: NCT02149940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: heart-failure related pharmaceutical intervention
Study: NCT02255409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)
Description: 1 dose 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: non-adjuvanted Quadrivalent Influenza Vaccine (QIV)
Description: 1 dose 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months
Study: NCT00617500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flower therapy
Description: Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic touch
Description: Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auricular therapy
Description: Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormones
Description: Estradiol 1 mg and a drospirenone 2mg/day (3 months)
Study: NCT04502485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric water exchange
Description: Upon entering the fundus of the stomach the air button will be turned off. Air pocket and gastric fluids will be removed by suctioning. Distilled water, delivered by a 50-ml syringe in 10ml-to-20 ml increments, will be infused to dislodge debris and air bubbles adhering the gastric mucosa and open the lumen. The infused water will be removed to keep the lumen almost completely collapsed before the scope advance further.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional air insufflation
Description: Air will be minimally insufflated and residual fluid suctioned during the entire insertion process. Usually, no water will be infused to cleanse the mucosa until the withdrawal phase.
Study: NCT04320732

Intervention type: BEHAVIORAL
Intervention: Observation of behavior and COVID-19 infection will be conducted.
Description: No intervention, only prospective observation of behavior will be conducted by a questionnaire.

Intervention type: BEHAVIORAL
Intervention: Observation of behavior and COVID-19 infection will be conducted.
Description: No intervention, only prospective observation of behavior will be conducted by a questionnaire.

Intervention type: BEHAVIORAL
Intervention: Observation of behavior and COVID-19 infection will be conducted.
Description: No intervention, only prospective observation of behavior will be conducted by a questionnaire.

Intervention type: BEHAVIORAL
Intervention: Observation of behavior and COVID-19 infection will be conducted.
Description: No intervention, only prospective observation of behavior will be conducted by a questionnaire.

Intervention type: BEHAVIORAL
Intervention: Observation of behavior and COVID-19 infection will be conducted.
Description: No intervention, only prospective observation of behavior will be conducted by a questionnaire.
Study: NCT04597983

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2S-hesperidin
Description: Cardiose® is a natural orange extract that due to its unique manufacturing process, maintains most of the natural hesperidin isomeric form (2S)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcellulose was used, this molecule was selected to avoid affecting the glycemia, as it can occur with dextrose or maltodextrin.
Study: NCT02445807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD06-Cream
Description: Twice daily topical application for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Twice daily topical application for 14 days.
Study: NCT01531309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGO178
Description: AGO178 is administered as a sublingual tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGO178
Description: AGO178 is administered as a sublingual tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGO178
Description: AGO178 is administered as a sublingual tablet.
Study: NCT02199938

Intervention type: OTHER
Intervention: Identification and characterization of molecular markers in musculoskeletal tumors
Study: NCT00113828

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant
Description: Rabbit anti-thymocyte globulin 0.5 mg/kg on transplant day-8, 2.5 mg/kg on day-7 and 3.0 mg/kg on day-6; cyclophosphamide 60 mg/kg on days-7,-6; fludarabine 25 mg/m2 on days -5, -4, -3, -2, -1.~Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-cell depleted peripheral blood stem cell transplant
Description: Rabbit anti-thymocyte globulin 0.5 mg/kg on transplant day-8, 2.5 mg/kg on day-7, 3.0 mg/kg on day-6; cyclophosphamide 60 mg/kg on days -7, -6; fludarabine 25 mg/m2 on days -5 through -1.~T-cell depleted peripheral blood stem cell transplant .
Study: NCT01643629

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Autologous Human Platelet Lysate (HPL)
Description: Study arm A will include subjects receiving three doses of Autologous Human Platelet Lysate at an interval of one month each.

Intervention type: OTHER
Group type: OTHER
Intervention: 2 % Minoxidil and /or Finasteride
Description: Control arm B subjects will receive Standard therapy (2% Minoxidil and/or Finasteride)
Study: NCT00400673

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Two-step remission induction and risk-oriented consolidation
Study: NCT02261194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Care Tools
Study: NCT04342000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Movement education workshop
Description: 30 minutes total:~* 10 minutes sedentary activity (LE injury risk factor and anatomy instruction)~* 10 minutes moderate activity (guided discovery of body segment alignment and stability with squat, lunge, plank, jump, and hop technique assessment and corrective feedback)~* 10 minutes vigorous activity (practical application of body segment alignment and stability including hopping, jumping, and running activities with technique assessment and corrective feedback)~For the month following the athlete workshop, prior to the final assessment, subjects will receive periodic text message instructions. These messages will include key facts and takeaways from the workshop, and reminders about correct form.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Education Workshop
Description: 30 minutes total:~* 10 minute sedentary activity (sleep, nutrition, and hydration instruction)~* 10 minutes moderate activity (performance of squat, lunge, plank, jump, and hop activities - no technique assessment or corrective feedback)~* 10 minutes vigorous activity (hopping, jumping, and running activities - no technique assessment and corrective feedback)
Study: NCT02216032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TMW Curriculum

Intervention type: OTHER
Group type: OTHER
Intervention: Nutrition Curriculum
Study: NCT00885274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pico-Salax
Description: Both doses of Pico-Salax taken the evening prior to colonoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Split Dose Pico-Salax
Description: One dose of Pico-Salax taken the evening prior to colonoscopy and the other the morning of the procedure.
Study: NCT02620696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: netazepide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: netazepide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: netazepide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: netazepide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: netazepide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: netazepide
Study: NCT03729063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Twice-daily expired carbon monoxide (CO) measurements
Description: Patients included in this arm will have expired CO measurements every morning and evening during their initial hospitalization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minimal control
Description: Patients included in this arm will have one expired CO measurement on the morning just after initial hospital admission and a second expired CO measurement one the morning prior to discharge.
Study: NCT00450723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosulfan blue
Description: Administered pre-surgery; injection of 2 cc of Isosulfan Blue in four equal aliquots of 0.5 cc as routinely done for the axillary sentinel node procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Lymph Node Dissection
Description: Axillary Lymph Node Dissection
Study: NCT01326949

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Description: Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach. Postoperatively, intravenous heparin (8,000-12,000 u/d) for five days, warfarin for six months were given.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ET+NSBB
Description: ET-Esophageal varices was treated by endoscopic variceal ligation (EVL). EVL was repeated at intervals of 1-2 weeks until the varices were obliterated or reduced to grade-I size.~NSBB-Propranolol started at a dose of 20mg twice a day. The dose is adjusted to the maximal tolerated doses to heart rate (HR) of 55 bpm or to decrease the HR 25% from baseline.~AT-A continuously intravenous infusion of unfractionated heparin followed by oral warfarin is employed. Initially, heparin is administered intravenously for 5 days. Subsequently, oral warfarin is prescribed at the dosage of 2.5 mg/d for 6 months or until complete portal vein recanalization and adjusted to maintain the INR at a target of 2.5 (range 2.0-3.0).
Study: NCT00450723

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: The surgery will be performed under general anesthesia with a single lumen endo-tracheal tube. The patient will be laid in a semi decubitus position on the opposite side with the ipsilateral arm bent over the head and attached to an arm rest.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy
Description: Sentinel Lymph Node Biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracoscopic Surgery
Description: Performed only if internal mammary sentinel node cannot be retrieved via same incision of lumpectomy/mastectomy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Technetium Tc 99m Sulfur Colloid
Description: Two to three hours prior to surgery, a peritumoral injection of filtered Technetium Sulfur Colloid will be performed in four 0.25 mci/2cc aliquots
Study: NCT01669161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivistim System
Description: The Vivistim System provides vagus nerve stimulation (VNS) with rehabilitation movements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehab Only
Description: Rehabilitation without device implant and VNS
Study: NCT03762369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-351
Description: twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D930
Description: three times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D930
Description: three times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of CKD-351
Description: once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of CKD-351
Description: twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of D930
Description: three times a day
Study: NCT04700839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Description: Sodium-glucose cotransporters inhibitors (SGLT2i) are novel hypoglycemic drugs with unique hypoglycemic mechanisms, which are completely independent of islet β-cell function or insulin sensitivity. Previous studies have shown that SGLT2i may improve IR by inhibiting glucotoxicity, reducing body weight, reducing inflammation, improving islet β-cell function, and reducing oxidative stress.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is a classic drug for the treatment of polycystic ovary syndrome, which can improve the degree of insulin resistance in PCOS patients.
Study: NCT00977236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthokeratology lenses
Description: Nightly use of orthokeratology to correct the refractive error and over-specs for a period of two years

Intervention type: DEVICE
Group type: OTHER
Intervention: Single-vision spectacle lenses
Description: Daily use of spectacles to correct the refractive error for a period of two years
Study: NCT03300999

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ginger tea
Description: 1. Ginger tea - Swanson Organic: 100% Certified Organic Ginger Root Tea~• Subjects will use one tea bag (contains two grams ginger root), mix with eight ounces of boiling water, steep for three minutes, and allow it to cool to room temperature before drinking. This will be done every day for one month before their third menstruation cycle and during their third menstruation cycle.
Study: NCT03215771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyoPro Motion-G
Description: The MyoPro Motion-G is an elbow-wrist-hand myoelectric orthosis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Learning-Based Therapy
Description: Motor learning-based (MLB) therapy included movement practice as close to normal as possible, high repetition, progression of challenge, part versus whole task practice, and knowledge of results. Treatment was customized to abilities of each subject and consisted of both MyoPro training and MLB therapy without device. Training with device was progressed using a hierarchy of challenge to increase complexity of movement. MLB therapy without device followed the same hierarchy, incorporating training of movements that could not be accomplished with the device and those that were trained with device. Movement quality was monitored and training practice was incrementally progressed as subject demonstrated improved ability to perform a given task/movement component. Subjects performed a custom home exercise program (HEP) on non-clinic days, increasing repetition as tolerated. At conclusion of in-clinic phase, individuals transitioned to a home phase where they continued to use the HEP.
Study: NCT00554567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Testing and Care Services
Description: Fully-decentralized HIV Voluntary Counseling and Testing and referral for care
Study: NCT03978195

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive device for middle ear ventilation
Description: Daily use of the device
Study: NCT03737383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: brief, trauma-focused treatment.
Study: NCT00772486

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISF35
Description: Subjects participating in this study will receive a course of three infusions of 3x10\^8 ISF35-transduced cells at periods of not less than 14 days apart followed by a standard regimen of three cycles of fludarabine, cyclophosphamide and rituximab (FCR) at monthly intervals.
Study: NCT02441465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Oral vemurafenib will be administered at a dose of 960 milligrams BID from Day 1 to Day 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-Labeled Vemurafenib
Description: IV infusion of 18.5 kilobecquerel (kBq) of 14C-labeled vemurafenib (3 milliliters \[mL\], which corresponds to a dose of 20 micrograms \[mcg\] of vemurafenib) on Day 21 (immediately after the morning oral dose of vemurafenib).
Study: NCT04784728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine topical system 1.8%
Description: lidocaine patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine topical system 1.8%
Description: lidocaine patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine topical system 1.8%
Description: lidocaine patch
Study: NCT04442945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAVEX3-71
Description: Active oral dose of ANAVEX3-71

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo
Study: NCT04444999

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carbon Dioxide Angiography
Description: • Automated carbon dioxide angiography: Patients are placed in the Trendelenburg position with the feet elevated of 10 º degrees. Carbon Dioxide automatic injection will be performed by digital Angiodroid injection system